ORTIF - ORTIF STOCK NEWS

Ortho Regenerative Technologies has announced the successful completion of the first patient surgery in its U.S. Phase I/II rotator cuff tear repair clinical trial, marking a significant milestone for the company. With eight clinical centers now fully initiated, patient enrollment is progressing, and additional surgeries are scheduled. The trial aims to evaluate the safety and efficacy of ORTHO-R as an adjunct to standard care surgery, enrolling a total of 78 patients across ten U.S. sites. The Phase I safety portion is expected to conclude by September, pending enrollment confirmation.

Ortho Regenerative Technologies Inc. (CSE: ORTH, OTCQB: ORTIF) announced progress in its U.S. Phase I/II clinical trial for rotator cuff tear repair. As of June 13, 2022, contracting procedures are completed for six of ten clinical trial sites, with five sites fully activated and actively screening patients. The company aims to report on key milestones, including patient recruitment and safety outcomes. CEO Philippe Deschamps expressed confidence in the trial's progress, emphasizing the sites' qualifications and patient volume.

Ortho Regenerative Technologies has secured a $500,000 grant from Axelys to advance its ORTHO-M technology for meniscus repair. This non-dilutive funding, obtained through a partnership with Polytechnique Montreal, underscores the potential of Ortho's drug/biologic combination product for various soft tissue repairs. The meniscus repair market in North America is valued at approximately $1 billion, with 600,000 surgeries performed annually, presenting a significant opportunity for Ortho. The grant aims to complete preclinical development for this high-value indication.

Ortho Regenerative Technologies Inc. (CSE: ORTH, OTC: ORTIF) has announced the issuance of a new patent by the U.S. Patent and Trademark Office, protecting its core intellectual property until 2035. This patent relates to the ORTHO-R soft tissue repair platform, enhancing the company's position in the regenerative medicine market. The patent covers both the composition and method for delivering Platelet-Rich Plasma (PRP) for soft tissue repair surgeries, validating Ortho's innovative approach and expanding its intellectual property portfolio to a total of ten patents.

Ortho Regenerative Technologies Inc. (CSE: ORTH, OTC: ORTIF) announced that its new CEO, Philippe Deschamps, will present at the 2022 Virtual Growth Conference from March 28-30. This event, hosted by Maxim Group LLC and M-Vest, will feature executives from various sectors, including biotech and healthcare. Attendees can expect company presentations and live Q&A sessions. Ortho focuses on developing novel soft tissue repair technologies, including its proprietary RESTORE platform, aimed at improving orthopedic surgery outcomes.

Ortho Regenerative Technologies has appointed Philippe Deschamps as President and CEO, effective immediately, following the retirement of Claude LeDuc. Deschamps brings extensive experience in the healthcare sector, having previously led companies and raised over $100 million for health products. The change aligns with the upcoming ORTHO-R Phase I/II clinical trial, which will assess a new soft tissue repair technology. The trial will enroll 78 patients across ten U.S. sites, marking a significant step in Ortho's clinical development.

Ortho Regenerative Technologies Inc. announced a non-brokered private placement aiming to raise $3.0 million. The offering consists of units priced at $0.30, each comprising one common share and one warrant, exercisable at $0.50 for 48 months. Closing is anticipated by February 28, 2022, pending regulatory approvals. Net proceeds will fund the ORTHO-R Phase I/II US Clinical trial and support general corporate purposes. This offering is available to accredited investors in Canada and the U.S., with finders receiving a 7% fee.

Ortho Regenerative Technologies has secured a Material Transfer Agreement with a leading global medical company for its ORTHO-R rotator cuff tear repair clinical trial. This partnership will provide exclusive access to a proprietary PRP system, enhancing the uniformity of treatment across trial sites. The Phase I/II study aims to evaluate ORTHO-R's efficacy compared to standard care in 78 patients across 10 U.S. sites. Early results from preclinical studies indicate ORTHO-R could significantly improve tissue repair, positioning it as a pioneering product in the orthobiologics sector.

Ortho Regenerative Technologies Inc. (CSE: ORTH, OTCQB: ORTIF) announced that the FDA has lifted the clinical hold on its IND application, allowing the company to proceed with its Phase I/II clinical trial for ORTHO-R. This trial aims to evaluate ORTHO-R as an adjunct treatment for rotator cuff tear repair surgery. The trial will enroll 78 patients across 10 U.S. sites. The clearance by the FDA confirms that Ortho has addressed all issues raised in the previous clinical hold letter, representing a significant milestone for the company.